This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
Our Story

Acepodia was spun-off from Professor Carolyn Bertozzi 's lab who won the 2022 Nobel Prize for Chemistry and founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche and Genentech, and by Dr. Sonny Hsiao, UC Berkeley cell biologist and inventor of Acepodia’s core technology. Acepodia is a privately held biotechnology company focused on developing innovative, highly effective cell therapies to treat cancers.

Our Mission

Acepodia is developing innovative, highly effective cell therapies by using ACC for cancer treatment that are immediately available to a broad group of patients.  

Our Difference

Acepodia is employing a flexible therapeutic design that leverages cutting edge technologies to develop the next generation of off-the-shelf cell therapies by unleashing the power of γδ2 T cells and NK cells to fight cancers.

Our first-of-its-kind approach is based on developing the most potent immune cell lines possible and equipping them with the optimal cellular targeting mechanisms needed to engage cancer cells with proprietary platform technologies. By arming our powerful cancer-killing cells with our tumor-targeting technology, Antibody-Cell Conjugation (ACC), Acepodia believes it can develop powerful, accessible cell therapies for patients with cancer.